Lymphocyte immune globulin, anti-thy (equine) Alternatives Compared
| Lymphocyte immune globulin, anti-thy (equine) | Filgrastim | Promacta (eltrombopag) |
|
|---|
| Lymphocyte immune globulin, anti-thy (equine) | Filgrastim | Promacta (eltrombopag) |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Aplastic Anemia, Renal Transplant. Lymphocyte immune globulin, anti-thy (equine) may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Neutropenia Associated with Chemotherapy, Neutropenia, Bone Marrow Transplantation, Aplastic Anemia, Neutropenia Associated with Radiation, Myelodysplastic Syndrome, Neutropenia... View more |
Prescription only
Promacta is an oral tablet or suspension that is taken daily to boost platelet numbers in people with chronic ITP, severe aplastic anemia, or chronic hepatitis C. Nausea, diarrhea, infections, and... View more |
Related suggestions Aplastic Anemia
|
|||||||
| More about Lymphocyte immune globulin, anti-thy (equine) | More about Filgrastim | More about Promacta (eltrombopag) | ||||||||
| Ratings & Reviews | ||||||||||
|
Be the first to share your experience with this drug. |
Filgrastim has an average rating of 8.7 out of 10 from a total of 10 ratings on Drugs.com. 78% of reviewers reported a positive effect, while 11% reported a negative effect. |
Promacta has an average rating of 7.3 out of 10 from a total of 18 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 20% reported a negative effect. |
||||||||
| Drug Class | ||||||||||
| Side Effects | ||||||||||
| Generic Availability | ||||||||||
|
N/A |
N/A |
|||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Promacta prices |
||||||||
| Dosage Forms Available | ||||||||||
|
N/A |
N/A |
|
||||||||
| Brand Names | ||||||||||
| Atgam | Neupogen, Nivestym, Nypozi, Releuko, Zarxio | Other eltrombopag brands include: Alvaiz, Promacta Kit | ||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||
|
208.8 hours |
5.8 hours |
35 hours |
||||||||
| CSA Schedule ** View glossary of terms | ||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | ||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | ||||||||||
|
A total of 166 drugs are known to interact with Lymphocyte immune globulin, anti-thy (equine):
|
A total of 175 drugs are known to interact with Filgrastim:
|
A total of 184 drugs are known to interact with Promacta:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||
| Disease Interactions | ||||||||||
| First Approval Date | ||||||||||
|
N/A |
N/A |
November 20, 2008 |
||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| More Information | ||||||||||
| Patient resources | ||||||||||
| Professional Resources | ||||||||||
| Related Treatment Guide | ||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.